CTMX CytomX Therapeutics Inc

Price (delayed)

$2.78

Market cap

$605.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$592.71M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized ...

Highlights
CTMX's equity has surged by 152% year-on-year but it is down by 6% since the previous quarter
CTMX's quick ratio has surged by 126% year-on-year but it is down by 10% since the previous quarter
The EPS has plunged by 188% YoY and by 22% from the previous quarter
CTMX's revenue has dropped by 87% year-on-year and by 49% since the previous quarter

Key stats

What are the main financial stats of CTMX

CTMX stock price

How has the CytomX Therapeutics stock price performed over time
Intraday
-5.44%
1 week
0.54%
1 month
-15.24%
1 year
31.75%
YTD
-34.74%
QTD
-25.87%

Financial performance

How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$18.3M
Gross profit
$18.3M
Operating income
-$87.15M
Net income
-$79.65M
Gross margin
100%
Net margin
-435.2%
The company's operating margin has shrunk by 162% QoQ
CTMX's net margin has dropped by 162% since the previous quarter
CTMX's revenue has dropped by 87% year-on-year and by 49% since the previous quarter
The gross profit has dropped by 87% year-on-year and by 49% since the previous quarter

Price vs fundamentals

How does CTMX's price correlate with its fundamentals

Growth

What is CytomX Therapeutics's growth rate over time

Valuation

What is CytomX Therapeutics stock price valuation
P/E
N/A
P/B
2
P/S
33.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.39
The EPS has plunged by 188% YoY and by 22% from the previous quarter
CTMX's equity has surged by 152% year-on-year but it is down by 6% since the previous quarter
The stock's price to book (P/B) is 51% less than its last 4 quarters average of 4.3
CTMX's revenue has dropped by 87% year-on-year and by 49% since the previous quarter
The stock's P/S is 74% more than its last 4 quarters average of 20.2

Efficiency

How efficient is CytomX Therapeutics business performance
CTMX's return on assets has dropped by 188% year-on-year and by 7% since the previous quarter
The ROS has plunged by 162% from the previous quarter
CTMX's ROE has dropped by 125% year-on-year and by 3.6% since the previous quarter
The ROIC has shrunk by 118% YoY but it has increased by 4.8% QoQ

Dividends

What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTMX.

Financial health

How did CytomX Therapeutics financials performed over time
CTMX's quick ratio has surged by 126% year-on-year but it is down by 10% since the previous quarter
The company's current ratio has surged by 123% YoY but it fell by 10% QoQ
CTMX's debt is 98% smaller than its equity
CTMX's equity has surged by 152% year-on-year but it is down by 6% since the previous quarter
CTMX's debt has surged by 100% since the previous quarter but it is down by 17% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.